SEARCH:   Advanced

Blood, 15 September 2008, Vol. 112, No. 6, pp. 2248-2260. Prepublished online as a Blood First Edition Paper on July 8, 2008; DOI 10.1182/blood-2008-03-145128. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-03-145128v1 112/6/2248    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mead, G. M. Articles by Jack, A. S. Search for Related Content PubMed PubMed Citation Articles by Mead, G. M. Articles by Jack, A. S. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Graham M. Mead1, Sharon L. Barrans2, Wendi Qian3, Jan Walewski4, John A. Radford5, Max Wolf6, Simon M. Clawson3, Sally P. Stenning3, Claire L. Yule3, Andrew S. Jack2, on behalf of the UK National Cancer Research Institute Lymphoma Clinical Studies Group and the Australasian Leukaemia and Lymphoma Group 1 Southampton University Hospitals Trust, Southampton, United Kingdom; 2 Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, United Kingdom; 3 MRC Clinical Trials Unit, London, United Kingdom; 4 MSCM Cancer Center, Warsaw, Poland; 5 Christie Hospital, Manchester, United Kingdom; and 6 Peter MacCallum Cancer Centre, Melbourne, Australia This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified (dm) CODOX-M/IVAC in patients diagnosed using these criteria. The study was open to patients with an aggressive B-cell lymphoma with an MKI67 fraction approaching 100%. Immunophenotype and fluorescent in situ hybridization (FISH) were used to separate BL from other aggressive B-cell lymphomas. BL was characterized by the presence of a cMYC rearrangement as a sole cytogenetic abnormality occurring in patients with a germinal center phenotype with absence of BCL-2 expression and abnormal TP53 expression. A total of 128 patients were eligible for the study, of whom 58 were considered to have BL and 70 to have diffuse large B-cell lymphoma (DLBCL). There were 110 clinically fit patients who received dmCODOX-M (methotrexate, dose 3 g/m2) with or without IVAC according to risk group. The 2-year progression-free survival was 64% (95% confidence interval [CI] 51%-77%) for BL, 55% (95% CI 42%-66%) for DLBCL, 85% (95% CI 73%-97%) for low risk, and 49% (95% CI 38%-60%) for high-risk patients. The observed differences in outcome and other clinical features validate the proposed diagnostic criteria. Compared with the previous trial LY06 with full-dose methotrexate (6.7 g/m2), there was a reduction in toxicity with comparable outcomes. This study was registered at www.clinicaltrials.gov as NCT00040690 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome Eleni Tholouli, Simon Watt, Guy S. Lucas, John Burthem, John A. Liu Yin, Jim Cavet, Hayley Greenfield, and John B. Houghton Blood 2009 114: 485-486. [Full Text] [PDF] Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma Andrew S. Jack, Sharon L. Barrans, Wendi Qian, Sally P. Stenning, and Graham M. Mead Blood 2009 114: 486-487. [Full Text] [PDF] This article has been cited by other articles: K. J. Savage, N. A. Johnson, S. Ben-Neriah, J. M. Connors, L. H. Sehn, P. Farinha, D. E. Horsman, and R. D. Gascoyne MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood, October 22, 2009; 114(17): 3533 - 3537. [Abstract] [Full Text] [PDF] E. Tholouli, S. Watt, G. S. Lucas, J. Burthem, J. A. L. Yin, J. Cavet, H. Greenfield, and J. B. Houghton Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome Blood, July 9, 2009; 114(2): 485 - 486. [Full Text] [PDF] A. S. Jack, S. L. Barrans, W. Qian, S. P. Stenning, and G. M. Mead Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma Blood, July 9, 2009; 114(2): 486 - 487. [Full Text] [PDF] Diagnosis and Treatment of Burkitt Lymphoma Journal Watch Oncology and Hematology, November 4, 2008; 2008(1104): 2 - 2. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020